GSK Resets China Strategy With Voluntary Price Cuts
This article was originally published in PharmAsia News
Executive Summary
Multinational drug companies in the past have generally been highly cautious about lowering prices for fear of triggering a chain reaction and downward spiral. A rare move by GSK in China highlights a dilemma facing such firms as their growth in this market slows significantly – should you exchange price reductions for volume growth or maintain current policies?